Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.

Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, Thakur GA.

J Med Chem. 2020 Jan 23;63(2):542-568. doi: 10.1021/acs.jmedchem.9b01142. Epub 2020 Jan 3.

PMID:
31756109
2.

A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain.

Soliman N, Hohmann AG, Haroutounian S, Wever K, Rice ASC, Finn DP.

Pain Rep. 2019 Jul 22;4(4):e766. doi: 10.1097/PR9.0000000000000766. eCollection 2019 Jul-Aug. Review.

3.
4.

Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats.

Ferris CF, Nodine S, Pottala T, Cai X, Knox TM, Fofana FH, Kim S, Kulkarni P, Crystal JD, Hohmann AG.

Neurobiol Pain. 2019 May 27;6:100034. doi: 10.1016/j.ynpai.2019.100034. eCollection 2019 Aug-Dec.

5.

Physiological, Anthropometric, and Motor Characteristics of Elite Chinese Youth Athletes From Six Different Sports.

Zhao K, Hohmann A, Chang Y, Zhang B, Pion J, Gao B.

Front Physiol. 2019 Apr 12;10:405. doi: 10.3389/fphys.2019.00405. eCollection 2019.

7.

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djz011. [Epub ahead of print]

PMID:
30715378
8.

Imaging Mass Spectrometry and Proteome Analysis of Marek's Disease Virus-Induced Tumors.

Pauker VI, Bertzbach LD, Hohmann A, Kheimar A, Teifke JP, Mettenleiter TC, Karger A, Kaufer BB.

mSphere. 2019 Jan 16;4(1). pii: e00569-18. doi: 10.1128/mSphere.00569-18.

9.

Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.

Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30.

PMID:
30504240
10.
11.

( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.

Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP.

J Med Chem. 2018 Oct 11;61(19):8639-8657. doi: 10.1021/acs.jmedchem.8b00611. Epub 2018 Sep 21.

PMID:
30196704
12.

ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.

Lee WH, Carey LM, Li LL, Xu Z, Lai YY, Courtney MJ, Hohmann AG.

Mol Pain. 2018 Jan-Dec;14:1744806918801224. doi: 10.1177/1744806918801224. Epub 2018 Aug 29.

13.

Parallelized Monte Carlo software to efficiently simulate the light propagation in arbitrarily shaped objects and aligned scattering media.

Zoller CJ, Hohmann A, Foschum F, Geiger S, Geiger M, Ertl TP, Kienle A.

J Biomed Opt. 2018 Jun;23(6):1-12. doi: 10.1117/1.JBO.23.6.065004.

14.

Replay of Episodic Memories in the Rat.

Panoz-Brown D, Iyer V, Carey LM, Sluka CM, Rajic G, Kestenman J, Gentry M, Brotheridge S, Somekh I, Corbin HE, Tucker KG, Almeida B, Hex SB, Garcia KD, Hohmann AG, Crystal JD.

Curr Biol. 2018 May 21;28(10):1628-1634.e7. doi: 10.1016/j.cub.2018.04.006. Epub 2018 May 10.

15.

Influence of Endurance Training During Childhood on Total Hemoglobin Mass.

Prommer N, Wachsmuth N, Thieme I, Wachsmuth C, Mancera-Soto EM, Hohmann A, Schmidt WFJ.

Front Physiol. 2018 Mar 21;9:251. doi: 10.3389/fphys.2018.00251. eCollection 2018.

16.

Reverse Engineering Tone-Deafness: Disrupting Pitch-Matching by Creating Temporary Dysfunctions in the Auditory-Motor Network.

Hohmann A, Loui P, Li CH, Schlaug G.

Front Hum Neurosci. 2018 Jan 30;12:9. doi: 10.3389/fnhum.2018.00009. eCollection 2018.

17.

Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice.

Lee WH, Li LL, Chawla A, Hudmon A, Lai YY, Courtney MJ, Hohmann AG.

Pain. 2018 May;159(5):849-863. doi: 10.1097/j.pain.0000000000001152.

18.

Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.

Lin X, Dhopeshwarkar AS, Huibregtse M, Mackie K, Hohmann AG.

Mol Pharmacol. 2018 Feb;93(2):49-62. doi: 10.1124/mol.117.109355. Epub 2017 Nov 30.

19.

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.

Biol Psychiatry. 2018 Nov 15;84(10):722-733. doi: 10.1016/j.biopsych.2017.06.032. Epub 2017 Jul 8.

20.

The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory.

Panoz-Brown D, Carey LM, Smith AE, Gentry M, Sluka CM, Corbin HE, Wu JE, Hohmann AG, Crystal JD.

Neurobiol Learn Mem. 2017 Oct;144:259-270. doi: 10.1016/j.nlm.2017.08.001. Epub 2017 Aug 12.

21.

The cannabinoid system and pain.

Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V.

Neuropharmacology. 2017 Sep 15;124:105-120. doi: 10.1016/j.neuropharm.2017.06.015. Epub 2017 Jun 15. Review.

22.

Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.

Li AL, Carey LM, Mackie K, Hohmann AG.

J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7.

23.

Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice.

Carey LM, Gutierrez T, Deng L, Lee WH, Mackie K, Hohmann AG.

Sci Rep. 2017 Apr 20;7(1):944. doi: 10.1038/s41598-017-01062-2.

24.

Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats.

Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG.

Neuroscience. 2017 May 4;349:303-317. doi: 10.1016/j.neuroscience.2017.02.055. Epub 2017 Mar 8.

25.

The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.

Smith AE, Slivicki RA, Hohmann AG, Crystal JD.

Behav Brain Res. 2017 Mar 1;320:48-57. doi: 10.1016/j.bbr.2016.11.042. Epub 2016 Nov 28.

26.

Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG.

Pharmacol Res. 2016 Dec;114:75-89. doi: 10.1016/j.phrs.2016.10.007. Epub 2016 Oct 20.

27.

Broadband Optical Properties of Milk.

Stocker S, Foschum F, Krauter P, Bergmann F, Hohmann A, Scalfi Happ C, Kienle A.

Appl Spectrosc. 2017 May;71(5):951-962. doi: 10.1177/0003702816666289. Epub 2016 Oct 21.

PMID:
27770046
28.

Inorganic Double Helices in Semiconducting SnIP.

Pfister D, Schäfer K, Ott C, Gerke B, Pöttgen R, Janka O, Baumgartner M, Efimova A, Hohmann A, Schmidt P, Venkatachalam S, van Wüllen L, Schürmann U, Kienle L, Duppel V, Parzinger E, Miller B, Becker J, Holleitner A, Weihrich R, Nilges T.

Adv Mater. 2016 Nov;28(44):9783-9791. doi: 10.1002/adma.201603135. Epub 2016 Sep 14.

PMID:
27624093
29.

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.

Hohmann AF, Martin LJ, Minder JL, Roe JS, Shi J, Steurer S, Bader G, McConnell D, Pearson M, Gerstberger T, Gottschamel T, Thompson D, Suzuki Y, Koegl M, Vakoc CR.

Nat Chem Biol. 2016 Sep;12(9):672-9. doi: 10.1038/nchembio.2115. Epub 2016 Jul 4.

30.

Predictive models reduce talent development costs in female gymnastics.

Pion J, Hohmann A, Liu T, Lenoir M, Segers V.

J Sports Sci. 2017 Apr;35(8):806-811. doi: 10.1080/02640414.2016.1192669. Epub 2016 Jun 7.

PMID:
27267568
31.

A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.

Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG.

Mol Pain. 2016 May 13;12. pii: 1744806916649192. doi: 10.1177/1744806916649192. Print 2016.

32.

BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.

Bhagwat AS, Roe JS, Mok BYL, Hohmann AF, Shi J, Vakoc CR.

Cell Rep. 2016 Apr 19;15(3):519-530. doi: 10.1016/j.celrep.2016.03.054. Epub 2016 Apr 7.

33.

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D.

J Med Chem. 2016 May 26;59(10):4462-75. doi: 10.1021/acs.jmedchem.5b01865. Epub 2016 Mar 10.

34.

Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors.

Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD.

Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. Epub 2016 Feb 22.

35.

Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo.

Slivicki RA, Ali YO, Lu HC, Hohmann AG.

PLoS One. 2016 Jan 25;11(1):e0147620. doi: 10.1371/journal.pone.0147620. eCollection 2016.

36.

Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics.

Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG.

Neuropharmacology. 2015 Oct;97:464-75. doi: 10.1016/j.neuropharm.2015.05.038. Epub 2015 Jun 10.

37.

Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase.

Marcus DJ, Zee M, Hughes A, Yuill MB, Hohmann AG, Mackie K, Guindon J, Morgan DJ.

Mol Pain. 2015 Jun 12;11:34. doi: 10.1186/s12990-015-0031-4.

38.

The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer.

Wang E, Kawaoka S, Roe JS, Shi J, Hohmann AF, Xu Y, Bhagwat AS, Suzuki Y, Kinney JB, Vakoc CR.

Elife. 2015 Apr 28;4:e06377. doi: 10.7554/eLife.06377.

39.

CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Deng L, Cornett BL, Mackie K, Hohmann AG.

Mol Pharmacol. 2015 Jul;88(1):64-74. doi: 10.1124/mol.115.098483. Epub 2015 Apr 22.

40.

Monte Carlo modeling of polarized light propagation: Stokes vs. Jones. Part II.

Günhan Akarçay H, Hohmann A, Kienle A, Frenz M, Rička J.

Appl Opt. 2014 Nov 1;53(31):7586-602. doi: 10.1364/AO.53.007586.

PMID:
25402927
41.

Monte Carlo modeling of polarized light propagation: Stokes vs. Jones. Part I.

Günhan Akarçay H, Hohmann A, Kienle A, Frenz M, Rička J.

Appl Opt. 2014 Nov 1;53(31):7576-85. doi: 10.1364/AO.53.007576.

PMID:
25402926
42.

A lipid gate for the peripheral control of pain.

Piomelli D, Hohmann AG, Seybold V, Hammock BD.

J Neurosci. 2014 Nov 12;34(46):15184-91. doi: 10.1523/JNEUROSCI.3475-14.2014. Review.

44.

A rationale to target the SWI/SNF complex for cancer therapy.

Hohmann AF, Vakoc CR.

Trends Genet. 2014 Aug;30(8):356-63. doi: 10.1016/j.tig.2014.05.001. Epub 2014 Jun 3. Review.

45.

Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.

Biol Psychiatry. 2015 Mar 1;77(5):475-87. doi: 10.1016/j.biopsych.2014.04.009. Epub 2014 Apr 25.

46.

Multiple scattering of polarized light: influence of absorption.

Hohmann A, Voit F, Schäfer J, Kienle A.

Phys Med Biol. 2014 Jun 7;59(11):2583-97. doi: 10.1088/0031-9155/59/11/2583. Epub 2014 May 1.

PMID:
24785964
47.

Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.

Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG.

Mol Pain. 2014 Apr 18;10:27. doi: 10.1186/1744-8069-10-27.

48.

Light propagation in structural anisotropic media in the steady-state and time domains.

Kienle A, Foschum F, Hohmann A.

Phys Med Biol. 2013 Sep 7;58(17):6205-23. doi: 10.1088/0031-9155/58/17/6205. Epub 2013 Aug 16.

PMID:
23948766
49.

Interlaboratory comparison of intact-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry results for identification and differentiation of Brucella spp.

Karger A, Melzer F, Timke M, Bettin B, Kostrzewa M, Nöckler K, Hohmann A, Tomaso H, Neubauer H, Al Dahouk S.

J Clin Microbiol. 2013 Sep;51(9):3123-6. doi: 10.1128/JCM.01720-13. Epub 2013 Jul 12.

50.

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Lynch ME, Cesar-Rittenberg P, Hohmann AG.

J Pain Symptom Manage. 2014 Jan;47(1):166-73. doi: 10.1016/j.jpainsymman.2013.02.018. Epub 2013 Jun 4.

Supplemental Content

Loading ...
Support Center